DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "T-Cell Immunotherapy Market (2nd Edition), 2017-2030" report to their offering.
The "T-Cell Immunotherapy Market, 2017-2030 (2nd edition)" report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. Immuno-oncology has been gradually nurtured by researchers over the last several years and is now considered as the fourth major pillar of cancer therapy, after surgery, chemotherapy and radiotherapy. As indicated earlier, the T-cell therapy market has evolved significantly over the last few years, offering promising opportunities for a variety of stakeholders.
The domain is characterized by a robust and opportunistic pipeline of product candidates focused on targeting hematological cancers and solid tumors. However, with no marketed products, this emerging field is still in its infancy. The report provides a comprehensive overview of the market, focusing particularly on CAR-T therapies, TCR therapies and TIL therapies.
The role of academic players/research institutes has been critical in this domain. Post the establishment of initial proof-of-concept, several industry players have entered into collaboration with non-industry participants to fund the clinical and commercial development of potential product candidates. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania), KTE-C19 and HPV-16 E6 TCR (Kite Pharma/National Cancer Institute), and LN-144 (Lion Biotechnologies/National Cancer Institute). As mentioned before, encouraging clinical results have significantly accelerated the progress of these therapies.
Several technology providers, especially those with capabilities in genome editing, and viral and non-viral gene transfer, are also actively involved in this emerging market. Many of these players have entered into partnerships with therapy developers in order to assist in designing novel features to enhance the efficacy and potency of existing T-cell therapies. A prominent example of such a technology is safety switches; these are innovative molecular tools designed to manage known side effects, such as cytokine release syndrome and B-cell aplasia, by allowing control over the expression of certain genes in the engineered cell population.
One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing programs of both small and big pharmaceutical firms in this domain. It is worth mentioning that there is a lot of hope pinned on multiple start-ups, which have received significant backing by several strategic investors and venture capital firms.
Key Topics Covered:
2. Executive Summary
4. Market Landscape
5. Chimeric Antigen Receptor-T (CAR-T) Cell Therapy
6. T-Cell Receptor (TCR) Based Therapies
7. Tumor Infiltrating Lymphocytes (TIL) Based Therapies
8. Market Opportunity
9. Key Therapeutic Areas for T-Cell Therapies
10. Emerging Technologies
11. Social Media: Emerging Trends
12. Partnerships and Collaborations
13. Venture Capital Support
14. Other T-Cell Immunotherapies
15. Case Study: Cell Therapy Manufacturing
16. T-Cell Immunotherapy: Cost Price Analysis
17. Company Profiles
18. Interview Transcripts
20. Appendix 1: Tabulated Data
21. Appendix 2: List of Companies and Organizations
For more information about this report visit http://www.researchandmarkets.com/research/fkgnpz/tcell